Patients With Esophageal Squamous Cell Carcinoma Respond to Camrelizumab/Apatinib Combo in Second-Line Setting

Article

Data presented at the 2021 Gastrointestinal Cancers Symposium shows promise for the combination of camrelizumab plus apatinib for previously treated patients with esophageal squamous cell carcinoma.

Results of a single-arm, open-label phase 2 study revealed positive clinical results coupled with an acceptable safety profile for camrelizumab (SHR-1210) plus apatinib (Rivoceranib) as therapy in the second-line setting for patients with esophageal squamous cell carcinoma (ESCC).

This study (NCT03736863), whose data were presented during the 2021 Gastrointestinal Cancers Symposium, was the first to explore the combination of a PD-1 inhibitor with an anti-angiogenesis inhibitor as second-line treatment for patients with advanced ESCC.

The anti–PD-1 monoclonal antibody camrelizumab induced significant improvements in overall survival (OS) and objective response rate (ORR) compared with chemotherapy in the randomized phase 3 ESCORT study of Chinese patients with advanced ESCC, but the absolute long-term survival benefit from PD-1 inhibitors remains limited. New treatment options that are effective in this patient population are needed, which led to the rationale for this study. The trial aimed to evaluate the safety and efficacy of camrelizumab in combination with the VEGFR2 inhibitor apatinib in the second-line setting.

The trial, which remains ongoing, is enrolling patients with unresectable locally advanced, locally recurrent, or metastatic ESCC across China. To be included in the study, patients must have an ECOG performance status of 0 or 1, be aged 18 to 75 years, and have progressed on or were intolerant to frontline chemotherapy. Camrelizumab was administered at 200 mg intravenously every 2 weeks, and apatinib was given at 250 mg orally daily in 4-week cycles. The primary end point is investigator-assessed ORR, and secondary end points include OS, progression-free survival (PFS), and disease control rate (DCR).

With a data cutoff date of November 16, 2020, a total of 46 patients had been enrolled from 9 sites and all were included in the full analysis set, as well as the safety analysis set. Thirty patients were evaluated in the per-protocol analysis set. The majority of patients were male (n = 38) and had an ECOG performance status of 1 (n = 34). The median age was 63 (range, 48-72) and metastatic sites included lymph nodes in 35 patients, lung in 9, and liver in 8. Forty-six patients had undergone prior chemotherapy, 33 had undergone surgery, and 17 received radiotherapy.

The ORR among 30 evaluable patients was 43.3%, with 4 patients achieving a complete response (CR) with camrelizumab, 9 achieving a partial response (PR), and 15 reaching stable disease (SD). After confirmation, 3 patients had a CR and 7 had a PR for an ORR of 33.3%. Patients who had a response to treatment demonstrated better tumor shrinkage than those who did not respond. The DCR was 93.3%.

The median PFS was 4.07 months with the combination (95% CI, 3.75-not available). The median 3-month OS rate was 82.2%, the 6-month rate was 67.6%, and the 9-month OS rate was 61.5%.

Overall, 33 patients (71.7%) experienced treatment-emergent adverse events (TEAEs), and these events were grade 3 or higher in 23 patients. The most common grade 3 or higher TEAEs included elevated aspartate aminotransferase in 7 patients (15.2%), elevated alanine transaminase in 5 (10.9%), elevated glutamyltransferase in 4 (8.7%), hemorrhage in 3 (6.5%), and increased total bilirubin, increased direct bilirubin, and esophageal fistula in 2 patients each (4.4%).

Eleven patients temporarily discontinued treatment or had a reduced dose of camrelizumab due to TEAEs.

In terms of any-grade immune-related AEs, 4 patients (8.7%) had thyroid function abnormalities, 2 (4.3%) had reactive capillary endothelial proliferation (RCEP), and 1 (2.2%) had pneumonitis. The only grade 3 or higher immune-related event was RCEP, which occurred in 1 patient (2.2%).

Patients received treatment until disease progression, unacceptable toxicity, patient withdrawal from the study, or investigator decision. Tumor response was evaluated every 2 cycles for the first 12 cycles of treatment, and then every 3 cycles thereafter by RECIST 1.1. AEs were assessed continuously for up to 90 days following the last dose of treatment.

Further randomized phase 3 clinical trials are warranted to further understand the efficacy and safety of camrelizumab plus apatinib in this patient population.

Reference:

Wang F, Wang J, Wu T, et al. Camrelizumab in combination with apatinib as second-line treatment for advanced esophageal squamous cell carcinoma: A single-arm, open-label, phase II study. J Clin Oncol. 2021;39(suppl 3):215.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content